Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | MMP7 | P09237 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2987274 | 1.00 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL4798136 | 1.00 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| Urea SCHEMBL29215668 | 0.94 | SLC1A3 (0.45) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL1133379 | 0.85 | GRIK1 (0.46) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL17213409 | 0.85 | GRIK1 (0.37) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL23688391 | 0.84 | GRIK1 (0.39) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL8017237 | 0.84 | GRIK1 (0.39) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL11199369 | 0.84 | GRIK1 (0.39) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL6530499 | 0.84 | GRIK1 (0.39) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 | |
| SCHEMBL6530502 | 0.84 | GRIK1 (0.39) | SLC1A3SLC1A2SLC1A1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103896794-B | The preparation method of aliskiren intermediate and aliskiren | CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY CHINESE ACADEMY OF SCIENCES (CN) | 2015-10-07 | — | — | CN | disclosed |
| EP-2062874-B1 | Process and intermediates for the preparation of aliskiren | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2014-12-17 | — | — | EP | disclosed |
| EP-2189442-B1 | Process and intermediates for the preparation of aliskiren | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2014-10-01 | — | — | EP | disclosed |
| EP-2189442-B1 | Process and intermediates for the preparation of aliskiren | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2014-10-01 | — | — | EP | disclosed |
| CN-103896794-A | Aliskiren intermediate and method for preparing aliskiren | CHANGCHUN APPLIED CHEMISTRY | 2014-07-02 | — | — | CN | disclosed |
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100184998-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| EP-2189442-A1 | Process and intermediates for the preparation of aliskiren | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2010-05-26 | — | — | EP | disclosed |
| EP-2189442-A1 | Process and intermediates for the preparation of aliskiren | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2010-05-26 | — | — | EP | disclosed |
| EP-2173698-A2 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF RENIN INHIBITORS SUCH AS ALISKIREN | Novartis Ag (CH) | 2010-04-14 | — | — | EP | disclosed |
| CN-101679178-A | Process for the synthesis of intermediates of renin inhibitors such as aliskiren | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2062874-A1 | Process and intermediates for the preparation of aliskiren | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008155338-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184998-A1 | ORGANIC COMPOUNDS | CYP1B1, CYP3A7, CYP2F1 | SLC1A3 3643/4885SLC1A2 3915/4885SLC1A1 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.